|
Partnering with Kendle in China can help open up your product R&D to significant numbers of special patient populations. With a population of more than a billion, the opportunity to conduct clinical trials in China, together with prosperous drug sales, provides potentially limitless pharmaceutical business possibilities.
As the first international CRO to enter China, we have conducted more than 60 studies in China since 1997. Currently, we provide a strategic base of operations in Beijing, China, with highly qualified, dedicated CRAs, all extensively trained in compliance with ICH GCP standards. All of our clinical monitoring staff holds a medical and/or pharmacy degree. With the advantage of broad patient population, accelerated patient recruitment, high trial quality and reasonable costs, we provide a strong presence as a leading CRO in China; offering full service Phase I - IV clinical trials.
Senior management in our Beijing office maintains a good working relationship with the State Food & Drug Administration (SFDA), China's regulatory agency. Knowledge of the Chinese regulatory processes, along with a strong working relationship with the SFDA, ensures that all the right regulatory requirements are met in a timely manner. We also help facilitate the regulatory process as the clinical trial progresses.
- Infectious Diseases
- CNS Diseases
- Oncology
- Gynecology and Obstetrics
- Cardiovascular
- Skeletal Diseases
- Respiratory Diseases
- Dermatology
- Gastroenterology
- Anesthesiology
- Endocrinology Metabolism
- Therapeutic Vaccines
- Genitourinary
|
